Received: 02 February 2026 Accepted: 11 February 2026 Published Date: 22 February 2026

ScienceFrontier
OPEN ACCESS

Biomedical Research and Clinical Advancements
ISSN Online: 3065-341X

Research ARTICLE

Diabetic Eye Disease: Contemporary Approaches to Diagnosis and Management

Ragni Kumari[1*] | Mrinal Ranjan Srivastava[2]

[1] *Assistant Professor & Head, Department of Optometry, Uttar Pradesh University of Medical Sciences (UPUMS), Saifai, Etawah, Uttar Pradesh, India*
[2] *Assistant Professor & Head, Department of Community Medicine, Pholo Jano Medical College, Dumka, Jharkhand, India*

***Corresponding Author:** Ragni Kumari. *Assistant Professor & Head, Department of Optometry, Uttar Pradesh University of Medical Sciences (UPUMS), Saifai, Etawah, Uttar Pradesh, India*

Citation: Ragni Kumari, Mrinal Ranjan Srivastava (2026). Diabetic Eye Disease: Contemporary Approaches to Diagnosis and Management, J *Biomedical Research and Clinical Advancements*; 3 (1) 41, **DOI:** *BRCA-RA-26-41*

Abstract:

Diabetic eye disease represents a major cause of visual impairment and blindness globally, particularly among working-age adults. It encompasses a spectrum of ocular complications, with diabetic retinopathy (DR) and diabetic macular edema (DME) being the most prevalent and vision-threatening manifestations. The pathophysiology of diabetic eye disease is multifactorial, involving chronic hyperglycemia-induced oxidative stress, inflammation, and microvascular dysfunction, which collectively compromise retinal integrity. Additionally, diabetes increases the risk of cataract formation, primary open-angle glaucoma, and neovascular glaucoma, further contributing to visual morbidity. Early diagnosis is critical to preventing irreversible damage. Advances in retinal imaging, including optical coherence tomography (OCT) and ultra-widefield fluorescein angiography, have revolutionized the ability to detect and monitor subtle retinal changes. Effective management relies on strict systemic control of blood glucose, blood pressure, and lipids, as well as ocular-specific treatments. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have become the cornerstone of therapy for DME and proliferative DR, often replacing traditional laser photocoagulation. Surgical options remain essential for advanced complications such as vitreous hemorrhage and tractional retinal detachment. Systemic factors—including duration of diabetes, glycemic control, hypertension, dyslipidemia, and renal status—significantly influence disease progression. A multidisciplinary approach that integrates ophthalmologic and systemic care is essential to optimize visual outcomes and quality of life for diabetic patients. This review summarizes the current understanding of the epidemiology, pathophysiology, clinical features, diagnostic strategies, and contemporary management of diabetic eye disease, highlighting areas for ongoing research and improvements in patient care.

Key words: diabetic retinopathy; diabetic macular edema; cataract; neovascular glaucoma; anti-vegf therapy; optical coherence tomography; retinal imaging; hyperglycemia; vision loss; diabetes mellitus

Introduction:

Diabetes mellitus is a chronic, multifactorial metabolic disease characterized by sustained hyperglycemia due to impairments in insulin secretion, insulin action, or both [1]. Over time, this metabolic dysregulation leads to a host of systemic microvascular and macrovascular complications. Among these, diabetic eye disease (DED) poses a major threat to vision and quality of life. It encompasses a spectrum of ocular disorders—including diabetic retinopathy (DR), diabetic macular edema (DME), neovascular glaucoma, and cataracts—with diabetic retinopathy being the most common and vision-threatening manifestation [2].

At its core, diabetic retinopathy results from chronic hyperglycemia-induced damage to the retinal microvasculature, leading to increased vascular permeability, capillary occlusion, ischemia, and pathological neovascularization. These changes are mediated by a cascade of biochemical pathways, including polyol pathway activation, oxidative stress, inflammation, and upregulation of vascular endothelial growth factor (VEGF) [3,4]. Left untreated, these changes can progress from non-proliferative diabetic retinopathy (NPDR) to proliferative diabetic retinopathy (PDR), significantly increasing the risk of irreversible vision loss [5].

Globally, the prevalence of diabetes has surged to epidemic proportions, with over 537 million adults affected as of 2021, a number projected to exceed 640 million by 2030 [6]. As a direct consequence, the burden of diabetic eye disease is also expanding. It remains one of the leading causes of preventable blindness, especially among individuals aged 20–64 years [7]. In low- and middle-income countries, where access to eye care and regular screening may be limited, the public health implications are even more profound [8].

Early detection and timely intervention are pivotal in mitigating the visual morbidity associated with DED. Clinical studies, such as the Diabetic Retinopathy Study (DRS) and the Early Treatment Diabetic Retinopathy Study (ETDRS), have established the efficacy of treatments like panretinal photocoagulation and focal laser therapy, while newer pharmacologic agents, notably anti-VEGF intravitreal injections, have revolutionized the management of DME and PDR [9,10].

However, successful management of diabetic eye disease extends beyond ophthalmic care. It requires a multidisciplinary approach, involving primary care providers, endocrinologists, ophthalmologists, and diabetes educators. Optimal systemic control of blood glucose, blood pressure, and lipid levels remains fundamental to preventing onset and progression [1,6].

This review aims to provide a comprehensive and clinically relevant overview of diabetic eye disease, focusing on epidemiology, pathophysiology, risk stratification, screening protocols, diagnostic advances, and current and emerging therapeutic strategies. A deeper understanding of these concepts will enable clinicians across specialties to enhance collaborative care and improve visual and systemic outcomes for patients with diabetes.

Epidemiology

The global burden of diabetes has reached epidemic proportions, with an estimated 537 million adults affected in 2021—a number projected to rise to 643 million by 2030 and 783 million by 2045, according to the International Diabetes Federation [11]. This surge is driven by a combination of demographic, lifestyle, and socioeconomic factors, including population aging, urbanization, poor dietary habits, physical inactivity, and increasing rates of obesity [12]. As the prevalence of diabetes grows, so too does the incidence of its complications—most notably diabetic eye disease, a major cause of visual impairment and blindness in the working-age population. Diabetic eye disease encompasses a spectrum of conditions, including diabetic retinopathy (DR), diabetic macular edema (DME), cataracts, and glaucoma, with DR being the most common and extensively studied manifestation [13].

Globally, approximately one in three people with diabetes develops some degree of diabetic retinopathy, and around 10% progress to vision-threatening diabetic retinopathy (VTDR), which includes proliferative diabetic retinopathy (PDR) and clinically significant diabetic macular edema [14]. The overall prevalence of DR varies by population and healthcare infrastructure, with higher rates reported in low- and middle-income countries (LMICs), where barriers to diabetes care, routine screening, and ophthalmic services are more pronounced. In these regions, late presentation, poor glycemic control, and limited access to advanced treatment modalities contribute to worse outcomes [15].

In contrast, high-income countries often demonstrate lower rates of vision-threatening disease, largely due to the widespread implementation of retinal screening programs, patient education, and timely access to treatment—including anti-VEGF therapies and laser photocoagulation. However, disparities persist even within developed countries, particularly among underserved or minority populations with limited access to care [16].

Diabetic macular edema (DME), a common cause of central vision loss in individuals with DR, affects approximately 6–7% of people with diabetes [17]. Unlike DR, which may remain asymptomatic in its early stages, DME can significantly impact visual acuity even in the absence of proliferative changes. DME can occur at any stage of DR and is driven by the breakdown of the blood-retinal barrier, leading to fluid accumulation in the macula [18].

Beyond DR and DME, individuals with diabetes are at increased risk for other sight-threatening ocular conditions. The risk of developing cataracts is two to five times higher in people with diabetes and tends to manifest at an earlier age. Cataracts may progress more rapidly, particularly in patients with poor glycemic control [19]. Similarly, the risk of glaucoma, particularly neovascular glaucoma, is increased, especially in patients with advanced DR, where retinal ischemia induces neovascularization of the iris and angle structures [20].

The cumulative burden of these complications poses significant challenges for both individual patients and healthcare systems. Diabetic eye disease contributes substantially to healthcare costs, lost productivity, and reduced quality of life. The World Health Organization and numerous public health agencies have identified diabetic eye disease as a priority target for vision preservation programs, emphasizing the need for:

- Early and regular retinal screening, preferably using digital fundus photography or teleophthalmology in resource-limited settings
- Timely intervention, including pharmacologic and surgical management of DR and DME
- Comprehensive systemic disease control, particularly for blood glucose, blood pressure, and lipid levels
- Public health strategies to increase awareness, education, and access to eye care services [21]

In summary, diabetic eye disease represents a major and growing public health concern worldwide. Understanding its epidemiology is critical for guiding screening strategies, allocating resources, and implementing policies that can prevent avoidable blindness in millions of people with diabetes [11].

Types of Diabetic Eye Disease:

Diabetic eye disease encompasses a range of ocular pathologies directly or indirectly caused by the metabolic and vascular consequences of diabetes mellitus. Understanding the distinct types is crucial for accurate diagnosis, risk stratification, and management. The major categories include diabetic retinopathy (DR), diabetic macular edema (DME), and other diabetes-associated ocular complications such as cataracts and glaucoma [22].

Diabetic Retinopathy (DR)

Diabetic retinopathy is the most prevalent and visually threatening complication of diabetes affecting the retina’s microvasculature. It is classically divided into two main stages based on the presence or absence of retinal neovascularization:

a) Non-Proliferative Diabetic Retinopathy (NPDR): Clinical features include [23]:

- Microaneurysms: Localized outpouchings of capillary walls, the earliest ophthalmoscopic sign.
- Retinal hemorrhages: Dot, blot, or flame-shaped due to ruptured vessels.
- Hard exudates: Lipid deposits from leaking capillaries.
- Venous beading and loops: Signs of retinal ischemia.
- Intraretinal microvascular abnormalities (IRMAs): Dilated capillaries that serve as shunts in ischemic areas. NPDR severity is graded as mild, moderate, or severe, with worsening ischemia and leakage correlating with progression.

b) Proliferative Diabetic Retinopathy (PDR): The advanced stage characterized by the formation of fragile new blood vessels (neovascularization) on the retinal surface, optic disc, or iris, driven by ischemia-induced angiogenic factors like VEGF [24]. Complications include:

- Vitreous hemorrhage from ruptured neovessels.
- Fibrovascular proliferation causing tractional retinal detachment.
- Neovascular glaucoma due to anterior segment neovascularization.

Diabetic Macular Edema (DME)

DME is the accumulation of extracellular fluid within the macula—the retinal area responsible for central, high-acuity vision—due to breakdown of the blood-retinal barrier and increased vascular permeability. It can occur at any stage of DR and is a leading cause of vision loss in diabetic patients [25]. DME is classified based on the involvement of the central macula (figure 1):

- Center-involving DME: Edema affects the fovea, causing significant visual impairment.
- Non-center-involving DME: Edema spares the fovea but may progress if untreated.



Figure 1: *Diabetic Retinopathy (DR)*

Other Diabetic Ocular Complications

While DR and DME account for most vision-threatening pathology in diabetes, several other ocular conditions are more common or aggravated by diabetes:
a) Diabetic Cataracts: Accelerated formation of lens opacities due to metabolic derangements such as polyol pathway flux, protein glycation, and oxidative stress. Cataracts develop earlier and progress faster in diabetics, contributing to decreased vision and complicating retinal assessment (figure 2) [26].



Figure 2: *Diabetic cataract*

b) Diabetic Glaucoma: Includes both increased prevalence of primary open-angle glaucoma (POAG) and neovascular glaucoma (NVG), the latter arising from proliferative ischemic retinopathy and characterized by neovascular obstruction of aqueous outflow, causing elevated intraocular pressure and optic nerve damage [27].
c) Other Less Common Entities: These include diabetic papillopathy (transient optic disc edema), ischemic optic neuropathy, and cranial nerve palsies, all of which may result from diabetes-induced microvascular compromise [28].
The classification of diabetic eye disease into these types facilitates targeted screening, monitoring, and treatment strategies. Clinicians must be aware that these entities often coexist and overlap, requiring a comprehensive approach to diagnosis and management to prevent irreversible vision loss [22].

Pathophysiology

Diabetic eye disease (DED) primarily encompasses diabetic retinopathy (DR) and diabetic macular edema (DME), both of which stem from chronic metabolic and vascular insults induced by persistent hyperglycemia. The disease process reflects a complex interplay of biochemical, cellular, and hemodynamic abnormalities culminating in microvascular dysfunction, retinal ischemia, and neurodegeneration [29].

Hyperglycemia-Induced Metabolic Pathways

Chronic hyperglycemia triggers multiple deleterious intracellular pathways that initiate and perpetuate retinal damage:

a) Polyol Pathway Flux

- Under hyperglycemic conditions, excess glucose is shunted into the polyol pathway, where aldose reductase reduces glucose to sorbitol using NADPH as a cofactor.
- Sorbitol accumulation leads to osmotic stress, causing cellular edema and dysfunction.
- Consumption of NADPH reduces availability for regenerating glutathione, weakening antioxidant defenses and promoting oxidative stress.
- Pericytes, which regulate capillary blood flow and structural integrity, are particularly susceptible to sorbitol-induced injury, leading to pericyte dropout, a hallmark of early DR [30].

b) Advanced Glycation End-products (AGEs)

- Non-enzymatic glycation of proteins and lipids results in AGEs, which accumulate in the retinal extracellular matrix and basement membranes.
- AGEs cross-link collagen fibers, thickening the basement membrane and altering vessel elasticity.
- Engagement of AGE receptors (RAGE) on retinal endothelial cells and macrophages triggers inflammatory signaling cascades, increasing pro-inflammatory cytokine release (e.g., TNF-α, IL-1β).
- AGEs induce oxidative stress and apoptosis, disrupting endothelial barrier function and exacerbating vascular leakage [31].

c) Protein Kinase C (PKC) Activation

- Hyperglycemia elevates diacylglycerol (DAG) concentrations, activating PKC isoforms, especially PKC-β.
- PKC influences multiple downstream effects:
    - Increases vascular permeability via phosphorylation of tight junction proteins.
    - Upregulates expression of VEGF and endothelin-1, promoting angiogenesis and vasoconstriction.
    - Promotes leukostasis by increasing adhesion molecule expression (ICAM-1, VCAM-1), leading to capillary occlusion [32].

d) Hexosamine Pathway

- Excess glucose is diverted into the hexosamine biosynthetic pathway, resulting in O-linked glycosylation of transcription factors and altered gene expression.
- This pathway increases transforming growth factor-beta (TGF-β) and plasminogen activator inhibitor-1 (PAI-1) production, enhancing extracellular matrix remodeling and fibrosis [33].

Oxidative Stress and Inflammation

- Chronic hyperglycemia causes mitochondrial dysfunction and overproduction of reactive oxygen species (ROS), damaging lipids, proteins, and DNA.
- Oxidative stress activates nuclear factor kappa B (NF-κB), inducing inflammatory cytokines and adhesion molecules, perpetuating leukocyte adhesion and endothelial injury.
- Inflammatory mediators such as IL-6, TNF-α, and MCP-1 recruit immune cells, creating chronic low-grade inflammation that worsens retinal microvascular damage.
- Leukostasis causes capillary occlusion and ischemia, driving retinal hypoxia and neovascularization [34].

Microvascular Structural Changes

- Pericyte loss and endothelial apoptosis compromise capillary stability and autoregulation.
- Capillary basement membrane thickening disrupts oxygen and nutrient exchange.
- Breakdown of endothelial tight junctions leads to blood-retinal barrier (BRB) disruption and increased vascular permeability.
- Capillary non-perfusion causes retinal ischemia, seen as capillary dropout on fluorescein angiography [35].

Retinal Ischemia and Neovascularization

- Retinal ischemia drives progression from NPDR to PDR.
- Hypoxia-inducible factor-1 alpha (HIF-1α) stabilizes under ischemia, stimulating VEGF transcription.

- VEGF promotes endothelial proliferation, migration, and neovascularization, especially on the optic disc and retinal surface.
- Fragile new vessels are prone to leakage, hemorrhage, vitreous hemorrhage, fibrovascular proliferation, and tractional retinal detachment [36].

Diabetic Macular Edema (DME) Pathogenesis

- Breakdown of the inner blood-retinal barrier due to tight junction disruption in retinal endothelial cells.
- VEGF-induced phosphorylation of tight junction proteins increases vascular permeability, allowing plasma leakage into the macula.
- Fluid accumulation forms cystoid spaces visible on OCT.
- Chronic edema causes photoreceptor dysfunction and apoptosis, correlating with vision loss [37].

Neurodegeneration in Diabetic Retinopathy

- Early neurodegenerative changes precede vascular lesions.
- Retinal ganglion cells, amacrine cells, and Müller glia undergo apoptosis due to glutamate excitotoxicity, oxidative stress, and impaired neurovascular coupling.
- Neurodegeneration contributes to functional deficits like contrast sensitivity loss and impaired color vision in early DR [38].

Additional Ocular Complications

A. Cataract Formation in Diabetes

- Polyol pathway activation causes sorbitol accumulation, osmotic stress, and cellular swelling in lens fibers.
- Protein glycation forms AGEs, modifying crystallins, causing aggregation and light scattering.
- Oxidative stress damages lens proteins; glutathione depletion impairs antioxidant defenses.
- Diabetic cataracts develop earlier, progress faster, often presenting as snowflake, cortical, or posterior subcapsular types.
- Cataracts impair fundus visualization, complicating DR monitoring and surgery [39].

B. Glaucoma in Diabetes

- Increased prevalence of primary open-angle glaucoma (POAG) and neovascular glaucoma (NVG).
- NVG arises from ischemic retina stimulating VEGF, causing iris and angle neovascularization (rubeosis iridis).
- Fibrovascular membranes obstruct aqueous outflow, raising intraocular pressure and damaging the optic nerve.
- NVG presents with pain, redness, vision loss, often requiring urgent intervention beyond medical therapy, including anti-VEGF, panretinal photocoagulation (PRP), and surgery [40].

Influence of Systemic Factors on Diabetic Eye Disease

A. Duration of Diabetes

- Longer diabetes duration correlates with increased DR severity.
- DR is rare in first 5 years of type 1 diabetes but almost universal after 20 years without control.
- Type 2 diabetes patients often have DR at diagnosis due to delayed detection [41].

B. Glycemic Control

- Intensive glucose lowering reduces DR risk and progression by ~50% (DCCT, UKPDS studies).
- Persistent hyperglycemia activates pathogenic pathways.
- Early control produces a “metabolic memory” protective effect [42].

C. Hypertension

- Elevates retinal capillary pressure, promotes leakage and ischemia.
- Tight control (<130/80 mmHg) reduces DR progression and cardiovascular risk [43].

D. Dyslipidemia

- Elevated LDL-C and triglycerides contribute to retinal lipid exudates and DME severity.
- Statins and lipid-lowering agents may reduce exudates and slow progression [44].

1. Clinical Presentation and Diagnosis

Clinical Presentation

Diabetic eye disease often progresses silently, especially in its early stages, making routine screening critical for early detection. Most patients with mild to moderate non-proliferative diabetic retinopathy (NPDR) are asymptomatic. Symptoms usually arise once diabetic macular edema (DME) or proliferative diabetic retinopathy (PDR) develops. Common symptoms include:

- Blurred or fluctuating vision
- Floaters or spots in the visual field caused by vitreous hemorrhage
- Difficulty with color perception
- Dark or empty areas in vision (scotomas)
- Sudden vision loss in cases of vitreous hemorrhage or retinal detachment

In advanced disease, patients may experience painful red eyes and elevated intraocular pressure in neovascular glaucoma [45].

Diagnosis

Accurate and timely diagnosis of diabetic eye disease (DED) is critical to preventing irreversible vision loss. Because early DR and DME are often asymptomatic, structured diagnostic approaches combining clinical examination, imaging, and grading scales are essential.

A. Clinical Examination

- **Visual Acuity Assessment:** Best-corrected visual acuity (BCVA) measurement is fundamental. Early NPDR may not impair acuity, but macular edema and advanced PDR often cause vision loss. Serial testing monitors functional impact.
- **Intraocular Pressure (IOP):** Elevated IOP may indicate glaucoma, including secondary neovascular glaucoma. Applanation tonometry is the gold standard. Early detection prevents optic nerve damage.
- **Anterior Segment Examination:** Slit-lamp biomicroscopy detects iris neovascularization (rubeosis iridis) and cataracts, which progress faster in diabetics.
- **Dilated Fundus Examination:** Using a 78D or 90D lens and binocular indirect ophthalmoscopy, detailed retinal evaluation includes:
  - Microaneurysms: Earliest sign of DR.
  - Intraretinal hemorrhages: Dot-blot or flame-shaped hemorrhages.
  - Hard exudates: Lipid deposits near leaking microaneurysms or edema.
  - Cotton wool spots: Retinal nerve fiber infarcts.
  - Venous beading and intraretinal microvascular abnormalities (IRMA): Indicators of worsening ischemia.
  - Neovascularization: Fragile new vessels characteristic of PDR.

Fundus exam remains the gold standard but requires skilled examiners and may miss subtle or peripheral lesions [46].

B. Imaging Techniques

- **Color Fundus Photography:**
  - *Standard 7-field ETDRS*: Research gold standard with stereoscopic images covering ~75° of retina for detailed grading.
  - *Single- or Two-field digital photography*: Common in screening; less comprehensive but cost-effective, enhanced by expert or AI interpretation.
  - *Ultra-widefield imaging*: Captures up to 200° retina, revealing peripheral lesions linked to DR progression risk.
- **Optical Coherence Tomography (OCT):** Provides micron-level cross-sectional retinal images for:
  - Quantifying retinal thickness to detect/monitor DME.
  - Visualizing cystoid spaces, subretinal fluid, epiretinal membranes, or vitreomacular traction.
  - Guiding initiation and monitoring of anti-VEGF therapy.
- **Optical Coherence Tomography Angiography (OCTA):** Noninvasive imaging of retinal microvasculature:
  - Maps superficial and deep capillary plexuses, highlighting capillary non-perfusion and microaneurysms.
  - Detects neovascular complexes via abnormal flow signals.
  - Enables earlier microvascular change detection than conventional imaging in some cases.
  - Limitations: motion artifacts and narrower field compared to fluorescein angiography.
- **Fluorescein Angiography (FA):** Gold standard for dynamic retinal vascular assessment:
  - Intravenous fluorescein dye injection with serial fundus photography.
  - Identifies capillary dropout, leakage, microaneurysms, and neovascularization with high sensitivity.
  - Differentiates focal vs diffuse DME, guides laser treatment, and detects macular ischemia.
  - Useful when clinical or OCT findings are ambiguous or for laser planning.

➢ Risks include allergic reactions and nausea [47].

C. Classification and Staging Systems

Precise staging informs prognosis and treatment. The **International Clinical Diabetic Retinopathy Disease Severity Scale**, endorsed by the American Academy of Ophthalmology and the American Diabetes Association, is the most widely used systemPrecise staging of diabetic eye disease informs prognosis and therapeutic decisions. Table 1 describe the most widely used system is the International Clinical Diabetic Retinopathy Disease Severity Scale, endorsed by the American Academy of Ophthalmology and the American Diabetes Association [48] (table 1and figure 3).

Table 1: Classification and Staging Systems

Stage	Key Features	Clinical Implications
No apparent retinopathy	No abnormalities detected	Routine annual screening recommended
Mild NPDR	Microaneurysms only	Low risk; continue annual or biennial follow-up
Moderate NPDR	More than microaneurysms but not meeting severe criteria	Increased risk; follow-up every 6-12 months
Severe NPDR	“4-2-1” rule: ≥20 hemorrhages in 4 quadrants, venous beading in ≥2 quadrants, or IRMA in ≥1 quadrant	High risk for progression to PDR; close monitoring and referral
Proliferative DR (PDR)	Neovascularization and/or vitreous/preretinal hemorrhage	Requires urgent treatment to prevent vision loss

Table 1: *Classification and Staging Systems*



Figure 3: *Stages of diabetic retinopathy*

Diabetic Macular Edema is classified based on center involvement (figure 4):

Non-center-involving DME: Retinal thickening or exudates outside the central macula, often monitored unless vision is affected.

Center-involving DME: Retinal thickening affecting the foveal center, usually necessitating treatment.



Figure 4: *Macular edema*

D. Integration of Systemic and Ocular Data

Diagnosis should not occur in isolation but rather as part of a multidisciplinary approach:

- Close collaboration with endocrinologists and primary care providers to optimize **glycemic control (HbA1c monitoring)**, blood pressure, and lipid management.
- Awareness of **renal status**, as nephropathy often parallels retinal disease severity.
- Patient education about the importance of **regular eye exams** and prompt reporting of visual symptoms.

The diagnosis of diabetic eye disease is a nuanced process that requires careful clinical examination supported by advanced multimodal imaging and standardized grading. Early identification of retinal pathology, especially in asymptomatic stages, enables timely intervention to prevent vision loss. The integration of cutting-edge diagnostic tools and evidence-based screening protocols, combined with systemic risk factor management, forms the cornerstone of comprehensive diabetic eye care.

E. Risk Factors

Several factors influence the development and progression of diabetic eye disease:

- **Duration of Diabetes:** Longer duration correlates strongly with increased risk. After 20 years of diabetes, nearly all type 1 and more than 60% of type 2 diabetics will have some degree of retinopathy.
- **Glycemic Control:** Poor blood glucose control, reflected by elevated HbA1c, is the most important modifiable risk factor.
- **Hypertension:** High blood pressure worsens retinal vascular damage and accelerates retinopathy progression.
- **Dyslipidemia:** Elevated cholesterol and triglycerides contribute to retinal hard exudate formation and macular edema.
- **Nephropathy:** Diabetic kidney disease is associated with more severe retinopathy.
- **Pregnancy:** Can accelerate retinopathy progression due to hormonal and hemodynamic changes.
- **Smoking:** Tobacco use aggravates microvascular complications.
- **Ethnicity:** Certain ethnic groups, including African Americans, Hispanics, and Native Americans, have higher susceptibility.

F. Screening and Monitoring

Given the often-asymptomatic nature of early diabetic eye disease, regular screening is critical to prevent vision loss.

- **Screening Recommendations:**
  - For type 1 diabetes: Initial dilated eye exam 5 years after diagnosis, then annually.
  - For type 2 diabetes: Initial exam at diagnosis, then annually.
  - More frequent exams may be required if retinopathy is detected or if risk factors are present.
- **Screening Modalities:**
  - Comprehensive dilated eye exams by ophthalmologists or optometrists.
  - Use of fundus photography with telemedicine is increasingly utilized to improve access, especially in remote areas.
  - OCT can be used to monitor macular edema progression.
- **Monitoring Disease Progression:**
  - Grading retinopathy severity helps guide treatment intervals and intervention.
  - Imaging and clinical exams should be tailored based on disease stage.

Early detection through screening programs has been shown to reduce rates of severe vision loss by facilitating timely treatment.
Routine screening is paramount because early DR is typically asymptomatic.

- **Type 1 Diabetes:** First comprehensive eye exam is recommended **within 3 to 5 years after diagnosis**, as retinopathy rarely develops before that.
- **Type 2 Diabetes:** Screening should occur **at diagnosis**, given the frequently delayed detection.
- **Pregnancy:** Pregnant women with pre-existing diabetes require examination **before conception or during the first trimester** and close follow-up every trimester due to risk of progression.

Screening intervals may vary from annually for those without retinopathy to every 3-6 months for those with severe NPDR or PDR.
Teleophthalmology and **automated AI-based image analysis** are emerging as valuable tools to expand screening access, especially in underserved or remote populations, improving early detection rates.

Management and Treatment

Management of diabetic eye disease requires a multidisciplinary approach aimed at controlling systemic risk factors, preserving vision, and treating ocular complications. Timely intervention can prevent or delay vision loss in most patients (table 2).

A. Medical Management Systemic Control

- **Glycemic Control:** Tight control of blood glucose levels remains the cornerstone of preventing and slowing diabetic eye disease progression. Landmark trials such as the Diabetes Control and Complications Trial (DCCT) and UK Prospective Diabetes Study (UKPDS) demonstrated that intensive glycemic control reduces the risk of retinopathy development and progression by 35-76% (49, 50).
- **Blood Pressure Management:** Controlling hypertension decreases the progression of retinopathy and incidence of macular edema. ACE inhibitors and ARBs have additional renal and ocular benefits (50).
- **Lipid Control:** Statins and fibrates reduce the risk of macular edema and slow retinopathy progression. The FIELD and ACCORD Eye studies showed fenofibrate reduces the need for laser treatment (51, 52).
- **Lifestyle Modifications:** Smoking cessation, regular exercise, and a healthy diet contribute to systemic risk reduction.

B. Pharmacological Ocular Treatments Anti-VEGF Therapy Vascular endothelial growth factor (VEGF) plays a key role in retinal neovascularization and vascular leakage. Anti-VEGF agents have revolutionized the treatment of diabetic retinopathy and diabetic macular edema (53, 54).

- **Common agents:** Ranibizumab (Lucentis), Aflibercept (Eylea), Bevacizumab (Avastin - off-label).
- **Indications:** First-line treatment for diabetic macular edema and proliferative diabetic retinopathy, especially when vision is threatened.
- **Efficacy:** Numerous clinical trials (e.g., RISE, RIDE, VIVID, VISTA) have demonstrated significant improvement in visual acuity and retinal thickness with repeated intravitreal injections.
- **Limitations:** Requires frequent injections, potential risks include endophthalmitis, intraocular pressure rise, and patient burden.

C. Corticosteroids Intravitreal corticosteroids (e.g., triamcinolone, dexamethasone implant) reduce inflammation and vascular permeability. They are used in cases refractory to anti-VEGF or when frequent injections are problematic. Side effects include cataract formation and elevated intraocular pressure.

D. Laser Therapy Focal/Grid Laser Photocoagulation

- Used primarily for diabetic macular edema to seal leaking microaneurysms and reduce fluid accumulation.
- Shown in the Early Treatment Diabetic Retinopathy Study (ETDRS) to reduce the risk of moderate vision loss by approximately 50%.
- The advent of anti-VEGF therapy has reduced the use of laser for DME but it remains an important option.

Panretinal Photocoagulation (PRP)

- Mainstay treatment for proliferative diabetic retinopathy.
- Laser is applied to the peripheral retina to reduce ischemia-driven VEGF production and cause regression of neovascularization.
- Can prevent vitreous hemorrhage and retinal detachment but may cause peripheral vision loss, night vision problems, and temporary worsening of macular edema.

E. Surgical Management Vitrectomy

- Indicated in advanced diabetic eye disease cases such as non-clearing vitreous hemorrhage, tractional retinal detachment, or combined tractional-rhegmatogenous detachment.
- The procedure involves removal of vitreous gel and blood to restore vision and prevent further retinal damage.
- Modern small-gauge vitrectomy techniques have improved safety and outcomes.

F. Emerging and Future Therapies

- Sustained-release drug delivery systems: Implants that reduce injection frequency, e.g., dexamethasone implant (Ozurdex), fluocinolone acetonide implant (Iluvien).
- New pharmacological targets: Agents targeting inflammation (e.g., IL-6 inhibitors), angiopoietin/Tie-2 pathway modulators, and neuroprotective drugs are under investigation.
- Gene therapy: Experimental approaches aiming to modify pathological angiogenesis or enhance retinal cell survival.
- Artificial intelligence (AI): Integration of AI in screening and grading diabetic retinopathy to improve access and early detection.

Treatment	Indications	Benefits	Limitations/Risks
Anti-VEGF agents	DME, PDR	Visual improvement, reduced edema	Frequent injections, cost, risks of infection
Corticosteroids	Refractory DME	Reduces inflammation	Cataracts, glaucoma
Focal/Grid Laser	DME	Reduces vision loss risk	Possible scotomas, limited visual improvement
Panretinal Laser	PDR	Regression of neovascularization	Peripheral vision loss, night vision problems
Vitrectomy	Vitreous hemorrhage, RD	Clears hemorrhage, repairs retina	Surgical risks, postoperative cataract

Table 2: *Treatment Modalities for Diabetic Eye Disease*

Prevention Strategies

Prevention of diabetic eye disease centers on minimizing risk factors and early detection through screening.

A. Optimal Systemic Control

- **Glycemic Control:** Intensive glucose management significantly reduces the incidence and progression of diabetic retinopathy and other eye complications. Maintaining HbA1c levels below 7% is recommended by major guidelines, balancing benefits and hypoglycemia risk (55, 56).
- **Blood Pressure Management:** Controlling hypertension to targets <130/80 mmHg reduces retinopathy risk and progression (57).
- **Lipid Management:** Use of statins and fibrates helps in reducing retinal hard exudates and macular edema (58, 59).
- **Lifestyle Interventions:** Smoking cessation, regular physical activity, and healthy diet contribute to systemic vascular health (60).

B. Regular Eye Screening

- Adherence to recommended screening intervals allows detection of early changes before vision loss occurs (61, 62).
- Education of patients and primary care providers improves compliance (63).
- Teleophthalmology programs increase access in underserved regions, enabling timely referrals (64, 65).

C. Patient Education and Awareness

- Informing patients about the importance of eye health and diabetes control empowers them to engage in preventive care (66).
- Awareness campaigns and community programs have shown positive impacts on screening rates (67).

Prognosis and Outcomes

The prognosis of diabetic eye disease depends heavily on early diagnosis and effective management. Without treatment, proliferative diabetic retinopathy and diabetic macular edema can lead to severe vision loss and blindness.

Factors Influencing Prognosis

- Stage at Diagnosis: Early-stage disease has a better prognosis (68).
- Systemic Control: Poor control of blood glucose and blood pressure worsen outcomes (69).
- Treatment Compliance: Regular follow-up and adherence to treatment improve visual prognosis (70).
- Access to Care: Geographic and socioeconomic barriers impact outcomes negatively (55).

Outcomes with Treatment

- Anti-VEGF therapy has dramatically improved visual outcomes in diabetic macular edema, with many patients experiencing significant vision gain (53, 54).
- Panretinal laser treatment reduces severe vision loss in proliferative diabetic retinopathy (52).
- Vitrectomy can restore vision in selected advanced cases but visual recovery may be limited if the macula is involved (50).

Despite advances, diabetic eye disease remains a leading cause of preventable blindness globally, highlighting the need for improved screening and treatment accessibility (56).

Future Directions and Research

Emerging research aims to further reduce the burden of diabetic eye disease through novel therapies and technologies.

A. Novel Therapeutic Targets

- Anti-inflammatory agents: Targeting inflammatory cytokines beyond VEGF to reduce vascular leakage and neurodegeneration (57, 59).
- Neuroprotective drugs: To preserve retinal neurons affected early in diabetes (58).
- Angiopoietin/Tie-2 Pathway Modulators: Investigational drugs modulating vascular stability show promise (60).

B. Drug Delivery Innovations

- Sustained-release implants and novel delivery systems aim to reduce treatment burden and improve compliance (61, 62).

C. Gene and Cell Therapy

- Early-stage research explores gene editing to inhibit pathological angiogenesis and stem cell therapy to regenerate damaged retinal cells (63, 64).

D. Artificial Intelligence and Telemedicine

- AI algorithms are being developed to improve screening efficiency and diagnostic accuracy (65, 66).
- Teleophthalmology is expanding to improve access to care, especially in remote and underserved populations (67).

E. Global Health Initiatives

- Efforts to integrate diabetic eye care into primary healthcare systems globally (68).
- Training healthcare workers and increasing public awareness to bridge gaps in care delivery (69, 70).

Conclusion

Diabetic eye disease represents a significant global public health challenge due to its high prevalence and potential to cause severe visual impairment. The pathophysiology involves complex microvascular and neurodegenerative processes driven by chronic hyperglycemia and associated metabolic disturbances. The disease spectrum includes diabetic retinopathy, diabetic macular edema, cataracts, and glaucoma.

Early detection through routine screening and comprehensive eye examinations is crucial, as many patients remain asymptomatic until advanced stages. Management requires a multifaceted approach involving tight systemic control of blood glucose, blood pressure, and lipids, alongside targeted ocular treatments including anti-VEGF agents, laser photocoagulation, and surgical intervention.
Advances in pharmacotherapy, imaging, and artificial intelligence have improved outcomes, yet barriers such as treatment access and patient adherence remain. Future research focusing on novel therapies and health system integration holds promise for further reducing the burden of diabetic eye disease.
Ultimately, coordinated efforts among patients, clinicians, and public health programs are essential to prevent vision loss and improve quality of life for individuals with diabetes.

References:

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* 1993;329(14):977-986.
   View at Google Scholar | View at Publisher
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in type 2 diabetes. *Lancet.* 1998;352(9131):837-853.
   View at Google Scholar | View at Publisher
3. Keech AC, Mitchell P, Summanen PA, et al. Effects of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study). *Lancet.* 2007;370(9600):1687-1697.
   View at Google Scholar | View at Publisher
4. ACCORD Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med.* 2010;363(3):233-244.
   View at Google Scholar | View at Publisher
5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS report number 1. *Arch Ophthalmol.* 1985;103(12):1796-1806.
   View at Google Scholar | View at Publisher
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med.* 1994;331(22):1480-1487. doi: *https://doi.org/10.1056/NEJM1994120133122*
   View at Google Scholar | View at Publisher
7. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med.* 2015;372(13):1193-1203. doi: *https://doi.org/10.1056/nejmoa1414264*
   View at Google Scholar | View at Publisher
8. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. *Ophthalmology.* 2014;121(10):1904-1914. doi:*https://doi.org/10.1016/j.ophtha.2014.04.024*
   View at Google Scholar | View at Publisher
9. Diabetic Retinopathy Clinical Research Network. Vitrectomy outcomes in patients with proliferative diabetic retinopathy and vitreous hemorrhage. *Ophthalmology.* 2006;113(3):341-347.
   View at Google Scholar | View at Publisher
10. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials. *Ophthalmology.* 2012;119(4):789-801.
    View at Google Scholar | View at Publisher
11. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology.* 2003;110(9):1677-1682. doi: *https://doi.org/10.1016/S0161-6420(03)00475-5*
    View at Google Scholar | View at Publisher
12. American Diabetes Association. Standards of Medical Care in Diabetes—2023. *Diabetes Care.* 2023;46(Supplement 1):S97-S110.
    View at Google Scholar | View at Publisher
13. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. *Diabetes Care.* 2003;26(9):2653-2664.doi: *https://doi.org/10.2337/diacare.26.9.2653*
    View at Google Scholar | View at Publisher
14. Bressler NM. Panretinal photocoagulation for proliferative diabetic retinopathy. *N Engl J Med.* 2017;376(13):1257-1266. **doi:** *https://doi.org/10.1056/NEJMct0908432*

View at Google Scholar | View at Publisher

15. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. *Diabetes.* 1997;46(9):1473-1480.doi: https://doi.org/10.2337/diab.46.9.1473
View at Google Scholar | View at Publisher
16. Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. *Ophthalmology.* 2018;125(10):1608-1622
doi: https://doi.org/10.1016/j.ophtha.2018.04.007
View at Google Scholar | View at Publisher
17. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. *Ophthalmology.* 2008;115(9):1447-1449.doi: https://doi.org/10.1016/j.ophtha.2008.06.015
View at Google Scholar | View at Publisher
18. Wells JA, Glassman AR, Ayala AR, et al. Long-term outcomes of ranibizumab treatment for diabetic macular edema: 5-year results. *Ophthalmology.* 2016;123(11):2376-2385.
View at Google Scholar | View at Publisher
19. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. *Ophthalmology.* 2014;121(10):1904-1914.doi: https://doi.org/10.1016/j.ophtha.2014.04.024
View at Google Scholar | View at Publisher
20. Campochiaro PA. Ocular neovascularization. *J Mol Med.* 2013;91(3):311-321.
View at Google Scholar | View at Publisher
21. Jonas JB, Tao Y. New insights in the pathophysiology and treatment of diabetic macular edema. *J Diabetes Res.* 2019;2019:4250186.
View at Google Scholar | View at Publisher
22. Chen E, Ghosh S, Jain S, et al. Vitrectomy for diabetic vitreous hemorrhage: visual outcomes and prognostic factors. *Clin Ophthalmol.* 2018;12:2003-2010.
View at Google Scholar | View at Publisher
23. Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of diabetic retinopathy. *Prog Retin Eye Res.* 2016;51:156-186.
doi: https://doi.org/10.1016/j.preteyeres.2015.08.001
View at Google Scholar | View at Publisher
24. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. *Lancet.* 2010;376(9735):124-136.
View at Google Scholar | View at Publisher
25. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. *Am J Ophthalmol.* 2005;140(3):509-516.doi: https://doi.org/10.1016/j.ajo.2005.03.057
View at Google Scholar | View at Publisher
26. Tso MO, Jampol LM. Pathophysiology of diabetic retinopathy. *Surv Ophthalmol.* 1982;27(4):221-230.
View at Google Scholar | View at Publisher
27. Jonas JB, Cheung CM, Panda-Jonas S. Updates on the epidemiology of diabetic retinopathy. *World J Diabetes.* 2017;8(6):489-500.
View at Google Scholar | View at Publisher
28. Nguyen QD, Shah SM, Khwaja AA, et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. *Ophthalmology.* 2010;117(11):2146-2151.doi: https://doi.org/10.1016/j.ophtha.2010.08.016
View at Google Scholar | View at Publisher
29. Abramoff MD, Lavin PT, Birch M, Shah N, Folk JC. Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. *NPJ Digit Med.* 2018;1:39.doi: https://doi.org/10.1038/s41746-018-0040-6
View at Google Scholar | View at Publisher
30. Ting DSW, Cheung CY-L, Lim G, et al. Development and validation of a deep learning system for diabetic retinopathy and related eye diseases using retinal images from multiethnic populations with diabetes. *JAMA.* 2017;318(22):2211-2223.doi: https://doi.org/10.1001/jama.2017.18152
View at Google Scholar | View at Publisher
31. Silva PS, Cavallerano JD, Sun JK, et al. Telemedicine for diabetic retinopathy: review and update. *Diabetes Technol Ther.* 2015;17(7): 508-517.
View at Google Scholar | View at Publisher

32. Huang Y, Cai X, Chen P, et al. Effects of lifestyle intervention on prevention of diabetes and diabetic retinopathy: a systematic review. *Int J Ophthalmol.* 2020;13(1):15-23.
View at Google Scholar | View at Publisher

33. American Academy of Ophthalmology Retina/Vitreous Panel. Preferred Practice Pattern® Guidelines. Diabetic Retinopathy. San Francisco, CA: AAO; 2019.
View at Google Scholar | View at Publisher

34. Wong TY, Sabanayagam C. Strategies to tackle the global burden of diabetic retinopathy: from epidemiology to artificial intelligence. *Ophthalmologica.* 2020;243(1):9-20.doi: *https://doi.org/10.1159/000502387*
View at Google Scholar | View at Publisher

35. Jampol LM, Glassman AR, Sun JK. Anti-vascular endothelial growth factor therapy for diabetic macular edema. *JAMA.* 2014;311(22):2283-2284.doi: *https://doi.org/10.1177/2042018813512360*
View at Google Scholar | View at Publisher

36. Cheung N, Wong IYH, Wong TY. Ocular anti-VEGF therapy for diabetic retinopathy: benefits and risks. *Lancet Diabetes Endocrinol.* 2014;2(10): 950-959.doi: *https://doi.org/10.2337/dc13-1990*
View at Google Scholar | View at Publisher

37. Holekamp NM, Sciborski CE, Goncalves A. Current clinical trial landscape for diabetic retinopathy. *Curr Opin Ophthalmol.* 2018;29(3):201-207.
View at Google Scholar | View at Publisher

38. Lyons TJ, Basu A. Biomarkers in diabetic retinopathy. *Curr Diabetes Rep.* 2012;12(4):329-341.doi: *https://doi.org/10.2147/DMSO.S32923*
View at Google Scholar | View at Publisher

39. Montero JA, del Olmo JA, Muñoz J. Gene therapy for diabetic retinopathy: basic science and clinical applications. *Int J Mol Sci.* 2021;22(6):3106.
View at Google Scholar | View at Publisher

40. Tomita M, Hata Y, Sakaguchi H, et al. Cell-based therapy for diabetic retinopathy: current status and future perspectives. *Stem Cells Int.* 2019;2019:2514318.
View at Google Scholar | View at Publisher

41. Campochiaro PA. Molecular pathogenesis of retinal and choroidal vascular diseases. *Prog Retin Eye Res.* 2015;49:67-81.
View at Google Scholar | View at Publisher

42. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology.* 2010;117(6):1064-1077.
View at Google Scholar | View at Publisher

43. Sohn EH, van Dijk HW, Jiao C, et al. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. *Proc Natl Acad Sci USA.* 2016;113(19):E2655-E2664.doi: *https://doi.org/10.1073/pnas.1522014113*
View at Google Scholar | View at Publisher

44. Wykoff CC, Flynn H, Brown DM, et al. Early vision improvements with anti-VEGF therapy in diabetic macular edema. *Ophthalmology.* 2017;124(3):271-277.
View at Google Scholar | View at Publisher

45. Hernandez C, Bogdanov P, Corraliza L, et al. Anti-inflammatory therapy in diabetic retinopathy. *J Diabetes Res.* 2017;2017:1481607.
View at Google Scholar | View at Publisher

46. Browning DJ. Pharmacologic treatment of diabetic retinopathy. *Expert Opin Pharmacother.* 2004;5(2):361-369.
View at Google Scholar | View at Publisher

47. Fisher DE, Ferris FL 3rd. The future of diabetic retinopathy research and treatment. *Am J Ophthalmol.* 2016;170:1-3.
View at Google Scholar | View at Publisher

48. Lam WC, Lo AC. Advances in treatment for diabetic retinopathy and diabetic macular edema. *J Ophthalmol.* 2016;2016:6394258.
View at Google Scholar | View at Publisher

49. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med.* 2005;353(25):2643-2653.
View at Google Scholar | View at Publisher

50. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ.* 1998;317(7160):703-713.doi: https://doi.org/10.1136/bmj.317.7160.703
View at Google Scholar | View at Publisher
51. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. *Lancet.* 2007;370(9600):1687-1697.
View at Google Scholar | View at Publisher
52. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med.* 2010;362(17):1563-1574.
View at Google Scholar | View at Publisher
53. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care.* 2012;35(3):556-564. doi: https://doi.org/10.2337/dc11-1909
View at Google Scholar | View at Publisher
54. Aiello LP. Vascular endothelial growth factor and diabetic retinopathy. *Surv Ophthalmol.* 1997;42(6):397-402.
View at Google Scholar | View at Publisher
55. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S1-S279. doi:10.2337/dc24-S001.doi: https://doi.org/10.2337/dc24-S001
View at Google Scholar | View at Publisher
56. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412. doi: https://doi.org/10.1136/bmj.321.7258.405
View at Google Scholar | View at Publisher
57. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713. https://doi.org/doi:10.1136/bmj.317.7160.703
View at Google Scholar | View at Publisher
58. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet. 2007;370(9600):1687-1697. doi: https://doi.org/10.1016/S0140-6736(07)61613-3
View at Google Scholar | View at Publisher
59. Chew EY, Ambrosius WT, Remaley NA, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-244. doi: https://doi.org/10.1056/NEJMoa1001288
View at Google Scholar | View at Publisher
60. Tan GS, Sabanayagam C, Banu R, et al. Physical activity and diabetic retinopathy: the Singapore Epidemiology of Eye Diseases Study. Br J Ophthalmol. 2017;101(5):578-583. doi: https://doi.org/10.1136/bjophthalmol-2016-309664
View at Google Scholar | View at Publisher
61. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991;98(5 Suppl):766-785.
View at Google Scholar | View at Publisher
62. Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110(9):1677-1682. doi: https://doi.org/10.1016/S0161-6420(03)00475-5
View at Google Scholar | View at Publisher
63. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med. 2010;27(3):249-256. doi: https://doi.org/10.1111/j.1464-5491.2009.02911.x
View at Google Scholar | View at Publisher
64. Silva PS, Cavallerano JD, Aiello LM, Aiello LP. Telemedicine and diabetic retinopathy: moving beyond retinal screening. Arch Ophthalmol. 2011;129(2):236-242. doi: https://doi.org/10.1001/archophthalmol.2010.346
View at Google Scholar | View at Publisher
65. Rajalakshmi R, Subashini R, Anjana RM, Mohan V. Automated diabetic retinopathy detection in smartphone-based fundus photography using artificial intelligence. Eye (Lond). 2018;32(6):1138-1144. doi: https://doi.org/10.1038/s41433-018-0072-6
View at Google Scholar | View at Publisher

66. Paul A, Khurana S, Kumar A. Impact of patient education on diabetic retinopathy screening uptake. Indian J Ophthalmol. 2017;65(6):487-489. doi: https://doi.org/10.4103/ijo.IJO_66_17
View at Google Scholar | View at Publisher

67. Piyasena MMPN, Murthy GVS, Yip JLY, Gilbert C. Improving patient uptake and adherence to diabetic retinopathy screening services: a systematic review of interventions. PLoS One. 2019;14(3):e0212656. doi: https://doi.org/10.1371/journal.pone.0212656
View at Google Scholar | View at Publisher

68. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464-1474. doi: https://doi.org/10.1016/S0161-6420(84)34438-8
View at Google Scholar | View at Publisher

69. Tapp RJ, Shaw JE, Harper CA, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003;26(6):1731-1737. doi: https://doi.org/10.2337/diacare.26.6.1731
View at Google Scholar | View at Publisher

70. Clemons TE, Chew EY, Bressler SB, McBee W. Age-related eye disease study research group. Age-related macular degeneration and cardiovascular disease: the age-related eye disease study. Arch Ophthalmol. 2005;123(10):1356-1364. doi: https://doi.org/10.1001/archopht.123.10.1356
View at Google Scholar | View at Publisher